Figure 7: Silencing of AKT2 modulates cell survival and expression of cell cycle arrest and apoptosis targets in SCC cells. (A). Cell viability assay. SCC-11 cells and SCC-11M cells were transfected with the scrambled (Scr) RNA or miR-29c-3p mimic and siRNA against AKT2. After 36hours posttransfection, cells were exposed to control media (CON) or 10μg/ml cisplatin (CIS) for 16hours.Assay was performed using five independent experiments in triplicate (*, p<0.05). (B). SCC-11 cells and SCC-11M cells were transfected with the scrambled (Scr) RNA, miR-29c-3p mimic and siRNA against AKT2 for 36hours, and subsequently treated with the control media (CON) or 10μg/ ml cisplatin (CIS) for 16hours. The CDK2, CCND, PUMA and CDKN1B expression and the phosphorylation of CDKN1B at T187, AMPK at T172 and p70S6K at T389 in SCC-11M cells were examined by immunoblotting with indicated antibodies. β-actin was used as a loading control.